✦ LIBER ✦

PCN126 OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

✍ Scribed by L. Heron; J. De Castro Carpeño; C. Chouaid; A. Vergnenègre; H.G. Bischoff; S. Walzer

Book ID: 119309736
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 74 KB
Volume: 14
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.02.980

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN71 Value of Progression-Free Survival

PCN71 Value of Progression-Free Survival (PFS) in Refractory Non-Small Cell Lung Cancer (NSCLC): An Exploratory Modeling Analysis

✍ Ferrufino, C.P.; Foley, D.; Trochlil, K.; Munakata, J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Factors affecting the association betwee

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer

✍ Aboshi, Masayuki; Kaneko, Masayuki; Narukawa, Mamoru 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 339 KB

Tumor response and progression-free surv

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer : Findings on the basis of North Central Cancer Treatment Group trials

✍ Nathan R. Foster; Yingwei Qi; Qian Shi; James E. Krook; John W. Kugler; James R. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

PCN16 MIXED TREATMENT COMPARISON OF BEVA

PCN16 MIXED TREATMENT COMPARISON OF BEVACIZUMAB-BASED THERAPIES RELATIVE TO DOUBLET-CHEMOTHERAPY COMBINATIONS TO ESTIMATE THE RELATIVE EFFICACY IN PROGRESSION-FREE SURVIVAL FOR TREATMENT OF FIRST-LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

✍ Y Yi; C Chouaid; A Vergnenegre; HG Bischoff; G Bergman; S Walzer; Z Philips 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

6570 POSTER Results for progression-free

6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology

✍ Sandler, A.; Reck, M.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB